Reallocation of fat that leads to an increase in visceral adiposity is one of the multiple factors involved in the development of T2DM in elderly people, but it is accompanied by a reduction in muscular mass (sarcopenia), lower sensitivity of pancreatic beta cells to incretins, pronounced rise in insulin resistance, decreased kidney function, lower physical activity, and comorbidities that imply the use of drugs with a potential diabetogenic effect [1,3,4,5]. This evidence concerns the gene INS and type 2 diabetes mellitus.